CRISPR gene editing medical research advancements

Recent clinical and laboratory research has demonstrated the potential of CRISPR-Cas9 gene-editing technology to treat various genetic conditions.

In the United States, researchers at Washington University in St. Louis conducted a clinical trial involving 30 patients with high-risk leukemia. By using CRISPR to eliminate the CD33 gene in donor stem cells, scientists aimed to protect new bone marrow from being destroyed by maintenance therapies. The study reported that all participants achieved neutrophil engraftment within 28 days, and patients receiving maintenance therapy tolerated the treatment without prolonged hematological toxicity.

In South Korea, researchers at Seoul St. Mary's Hospital demonstrated a proof-of-concept for treating Gitelman syndrome, a rare genetic kidney disorder. By inserting a functional SLC12A3 gene into induced pluripotent stem cells, the team created kidney organoids that regained significant protein levels for sodium and chloride transport. While the results showed physiological responsiveness, researchers noted that further studies in animal models are necessary to verify long-term safety and efficacy.